Stock Forecast

  Oncodesign Société Anonyme ( ALONC.PA) Stock. Should you Buy or Sell?    $ 14.34

-0.02 (-0.14 %)

Oncodesign Société Anonyme Analysis

Updated on 10-09-2022
Price $14.34
Beta 1.614
Volume Avg. $8.19 thousand
Market Cap $98.21 M
52 Week Range $7.83 - $14.56

Oncodesign Société Anonyme opened the day at $14.34 which is -0.14 % on yesterday's close. Oncodesign Société Anonyme has a 52 week high of $14.56 and 52 week low of $7.83, which is a difference of $6.73. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $98.21 M and total net profit is $36206580 which means the company is trading at 2.71 times profit to market capitalization. Theoretically, if you were to buy Oncodesign Société Anonyme for $98.21 M, it would take 15 years to get your money back. Oncodesign Société Anonyme are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Oncodesign Société Anonyme Stock Forecast - Is Oncodesign Société Anonyme a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreStrong Buy
PE ScoreStrong Buy
PB ScoreStrong Buy
Overall RecommendationStrong Buy

Growth and Value

PE Ratio 62.895
Dividend Yiel 0.000
Net Profit Margin 0.015

Valuing Oncodesign Société Anonyme

Price Book Value Ratio 8.643 Price To Book Ratio 8.643
Price To Sales Ratio 3.337 Price Earnings Ratio 226.838

How liquid is Oncodesign Société Anonyme

Current Ratio 0.955
Quick Ratio 0.575


Debt Ratio 0.808 Debt Equity Ratio 4.221
Long Term Debt To Capitalization 0.001 Total Debt To Capitalization 0.699

Latest news about Oncodesign Société Anonyme

About Oncodesign Société Anonyme

CEO : Dr. Philippe Genne
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : Paris

Description :

Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Oncodesign Société Anonyme has a strategic partnership with InterSystems for new treatments in the field of oncology; and Covalab. The company also has a collaboration agreement with TiumBio Co., Ltd. for the research and development of fibrosis drug candidates. Oncodesign Société Anonyme was founded in 1995 and is headquartered in Dijon, France.

My Newsletter

Sign Up For Updates & Newsletters